Navigation Links
Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
Date:2/12/2013

SUNNYVALE, Calif., Feb. 12, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (the "Company") (Nasdaq: PCYC) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to the investigational oral agent ibrutinib monotherapy for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) and to ibrutinib monotherapy for the treatment of patients with Waldenstrom's macroglobulinemia (WM), both of which are B-cell malignancies.

The Breakthrough Therapy Designation is intended to expedite the development and review of a potential new drug for serious or life-threatening diseases where "preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development."[i]  The designation of a drug as a Breakthrough Therapy was enacted as part of the 2012 Food and Drug Administration Safety and Innovation Act.

Pharmacylics, together with Janssen, is working with the FDA to determine the implications of this Breakthrough Therapy Designation to the ongoing and planned development and the filing requirements for the use of ibrutinib in patients with MCL and WM. The company expects to finalize the MCL filing prior to year end and will provide guidance on the WM filing after further discussions with the FDA. Pharmacyclics will provide regulatory updates as further information on implementing the requirements with respect to Breakthrough Therapies are developed by the Secretary of Health and Human Services.

"This is a historic moment in oncology. We are truly honored to have received this Breakthrough Designation and are pleased for patients and clinicians with the FDA's decision to expedite the development of ibrutinib,
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
2. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
3. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
4. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
5. Landauer, Inc. Reports Fiscal 2013 First Quarter Results
6. Misonix Reports Financial Results for First Half of Fiscal 2013
7. CareFusion Reports First Half Fiscal 2013 Results
8. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
9. American Pacific Reports Fiscal 2013 First Quarter Results; Reaffirms Full Year Guidance
10. European patient registry in venous thromboembolism (VTE) - PREFER in VTE - enrols first patient
11. Neutronic Ear Introduces Worlds First Rechargeable-Powered Hearing Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Perrigo Company (NYSE: ... has received an AB therapeutic equivalent rating from the ... approved New Drug Application (NDA) for testosterone gel 1.0%. ... to [AbbVie,s] AndroGel 1% and can be substituted with ... clinical effect and safety profile as AndroGel 1% when ...
(Date:7/24/2014)... KIRKLAND, Wash. , July 24, 2014 ... exhibiting at the 2014 National Association of State Veterans ... Carolina . The goal of the NASVH is ... receives the benefits, services, long term health care and ... sacrifice. With the InSite® Remote Dispensing ...
(Date:7/24/2014)... , July 24, 2014  Lazarus Effect, a ... novel interventional devices to facilitate removal of blood ... and Trademark Office has issued a new patent ... the company,s Lazarus Cover TM and ReCover ... ReCover is a single-component stent-retriever (stentriever) with an ...
Breaking Medicine Technology:Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3Talyst Exhibits at the National Association of State Veterans Homes Summer Conference 2Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2
... Healthcare, a world-leading developer, manufacturer and marketer of innovative ... that in connection with a refinancing of its debt ... in combination with new senior secured credit facilities, it ... Senior Notes. The offering of the new notes will ...
... YORK, Dec. 5, 2010 Pfizer Inc. (NYSE: ... Directors has elected Ian C. Read, 57, currently head ... Executive Officer and Director. Mr. Read succeeds Jeffrey B. ... (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) The Board,s Lead Independent ...
Cached Medicine Technology:ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 2ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 3Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 2Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 3Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 4
(Date:7/24/2014)... Voted one of the most reliable online dress suppliers ... providing its new and old customers with the latest ... announced its new collection of high end wedding dresses. ... to the latest fashion trends. Additionally, they are now ... As a matter of fact, high end special occasion ...
(Date:7/24/2014)... 2014 The federal judge overseeing ... in the U.S. District Court, District of Massachusetts, ... medical information covered by the federal Health Insurance ... 16th Order, U.S. District Judge Douglas P. Woodlock ... Care the right to receive HIPAA- protected information. ...
(Date:7/24/2014)... 24, 2014 CarePoint Health is ... hematology and oncology, Dr. Hitendra Upadhyaya, has joined ... welcomes Dr. Upadhyaya to the community. Hundreds of ... Medical Group, a comprehensive network of top doctors ... range of specialties. This latest acquisition represents CarePoint ...
(Date:7/24/2014)... treatment of overweight and obese preschoolers works better when ... only the child is targeted, according to research published ... the University at Buffalo and Women and Children,s Hospital ... or obese and had one parent who participated in ... to body mass index (BMI) measurements, calculated based on ...
(Date:7/24/2014)... between two or more equally positive outcomes experience ... with activity in different regions of the brain, ... associate research scholar at the Princeton Neuroscience Institute ... 42 people rated the desirability of more than ... looked at images of paired products with different ...
Breaking Medicine News(10 mins):Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Brain's dynamic duel underlies win-win choices 2Health News:Brain's dynamic duel underlies win-win choices 3
... ... since 1998, has now processed 1.5 million orders. The website provides lifestyle medications such as ... that is reviewed by a U.S.-licensed doctor. Visitors do not need to have a prescription ... ...
... ... Law & Technology,s information privacy programs and senior fellow to the Samuelson Law, Technology & ... Ad Ops Forum taking place in San Francisco on June 17. , ... (PRWEB) May 18, 2010 -- Chris Jay Hoofnagle, ...
... , ... consultancy providing unique IT solutions for the healthcare industry, announces a new whitepaper on the ... ... -- Arcadia Solutions , a national consultancy providing unique IT solutions for the healthcare ...
... ... on the ten distinct warning signs that foretell violence and the appropriate responses. “Workplace ... approaching the subject directly and honestly. , ... (PRWEB) May 18, 2010 -- Kantola Productions LLC has released ...
... effective way to convince young women to cut back on ... melanoma, the deadliest form of skin cancer, by 75 percent? ... "They,re not worried about skin cancer, but they are ... a professor of dermatology at Northwestern University Feinberg School of ...
... than thought, says a University of Florida researcher about a ... could lead to identifying those at risk for developmental disorders ... form of learning in sleeping newborns, a type of learning ... Byrd, a research affiliate in psychology at UF who collaborated ...
Cached Medicine News:Health News:Safe & Secure Online Pharmacy Viamedic.com; Reaches Milestone of 1.5 Million Orders Processed 2Health News:Chris Jay Hoofnagle to Deliver Keynote at the AdMonsters US Network Ad Ops Forum II, June 17, San Francisco 2Health News:Chris Jay Hoofnagle to Deliver Keynote at the AdMonsters US Network Ad Ops Forum II, June 17, San Francisco 3Health News:How Health Plans Can Turn Customer Touch Points into a Competitive Advantage – Whitepaper Release 2Health News:Kantola Productions Releases Workplace Violence Prevention Training Video 2Health News:Wrinkles are scarier than skin cancer for young tanners 2Health News:Wrinkles are scarier than skin cancer for young tanners 3Health News:Newborn infants learn while asleep; study may lead to later disability tests 2
... V is a low viscosity bone cement, ... vertebroplasty. The bone cement is injected into ... Osteopal V is used for the augmentation ... zirconium dioxide is included in the cement ...
Leadpoint Micro-Electrode Recording...
Based on the trusted Schaltenbrand-Wahren Atlas for Stereotaxy of the human brain, Atlasplan Software provides anatomical detail of the basal ganglia region of the brain and can help confirm target a...
Stereoplan, a three-dimensional software package for planning stereotactic procedures. Stereoplan provides diverse compatibility by supporting both the Radionics CRW frame and the Leksell G frame....
Medicine Products: